How have immunohistochemistry and immunofluorescence been adapted to fit the growing needs of the life science research ...

The immunohistochemistry (IHC) market is on a promising growth trajectory, with an anticipated value of USD 3.5 billion in ...

Immunoblotting and immunohistochemistry confirmed the loss of CDK12 protein. To describe more explicitly how the loss of ...

PsychoGenics Inc. (PsychoGenics) today announced it has been awarded a contract by the National Institutes of Health (NIH) to test and identify novel investigational therapeutics for the treatment of ...

Allied Market Research published a report, titled, "Breast Cancer Screening Market by Test Type (Blood Marker Test, Genetic Test, Imaging Test and Immunohistochemistry Test), by Gender (Male and ...

Melanoma-associated antigen A6 (MAGEA6) is well known to have oncogenic activity, but the underlying mechanisms by which it regulates tumor progression and chemo-resistance, especially in ...

The FDA will decide on new drugs for rosacea, AADC deficiency, breast cancer, transthyretin amyloid cardiomyopathy, and biliary tract cancer.

Siriraj Hospital excels in maintaining its high standards for every service, including diagnostics through the integration of ...

In this important study, the authors used a zebrafish model and scRNAseq analysis to show that a subset of keratinocytes within melanoma microenvironment highly up-regulate Twist and undergo ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of breast ...

Daiichi Sankyo submits Enhertu sNDA to Japan’s MHLF for patients with HER2 low or HER2 ultralow metastatic breast cancer ...

The firm sees potential for AI algorithms to support drug development by screening patients for biomarkers and predicting their responses to cancer therapies.